Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab

Cytotherapy

Volumn 18, Issue 8, 2016, Pages 1043-1055

  Bjoern, Jon ^a   Iversen, Trine Zeeberg ^a   Nitschke, Nikolaj Juul ^a   Andersen, Mads Hald ^a   Svane, Inge Marie ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

IDO; Indoleamine 2,3 Dioxygenase; Ipilimumab; Melanoma; Peptide vaccine

Indexed keywords

CORTICOSTEROID; DABRAFENIB; INDOLEAMINE 2,3 DIOXYGENASE; IPILIMUMAB; PEPTIDE VACCINE; VEMURAFENIB; CANCER VACCINE; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CHOROIDITIS; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; DIARRHEA; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; MALE; METASTATIC MELANOMA; MIDDLE AGED; MORTALITY; NAUSEA; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; ROSACEA; TREATMENT RESPONSE; ACTIVE IMMUNOTHERAPY; CHEMISTRY; CLINICAL TRIAL; IMMUNOLOGY; MELANOMA; METASTASIS; PATHOLOGY; PILOT STUDY; PROCEDURES; SKIN NEOPLASMS; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CANCER VACCINES; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PEPTIDE FRAGMENTS; PILOT PROJECTS; SKIN NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84991834357     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.05.010     Document Type: Article

References (59)

1. [1] Wilgenhof, S., Van Nuffel, A.M.T., Corthals, J., Heirman, C., Tuyaerts, S., Benteyn, D., et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 34 (2011), 448–456.
2. [2] Fang, R.H., Hu, C.-M.J., Luk, B.T., Gao, W., Copp, J.A., Tai, Y., et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett 14 (2014), 2181–2188.
3. [3] Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18 (2012), 1254–1261.
4. [4] Tarhini, A.A., Leng, S., Moschos, S.J., Yin, Y., Sander, C., Lin, Y., et al. Safety and Immunogenicity of Vaccination With MART-1 and Immunogenicity of Vaccination With MART-1 (26–35, 27L), gp100 (209–217, 210M), and Tyrosinase (368–376, 370D) In Adjuvant With PF-3512676 and GM-CSF. J Immunother 35 (2012), 359–366.
5. [5] Tran, E., Turcotte, S., Gros, A., Robbins, P.F., Lu, Y.-C., Dudley, M.E., et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344:6184 (2014), 641–645.
6. [6] Karanikas, V., Zamanakou, M., Kerenidi, T., Dahabreh, J., Hevas, A., Nakou, M., et al. Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 6 (2007), 1258–1262.
7. [7] Chevolet, I., Speeckaert, R., Haspeslagh, M., Neyns, B., Krüse, V., Schreuer, M., et al. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?. Br J Dermatol 171 (2014), 987–995.
8. [8] Lee, J.R., Dalton, R.R., Messina, J.L., Sharma, M.D., Smith, D.M., Burgess, R.E., et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 83:10 (2003), 1457–1466.
9. [9] Lob, S., Konigsrainer, A., Schafer, R., Rammensee, H.G., Opelz, G., Terness, P., Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111 (2008), 2152–2154.
10. [10] Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, G.J., Green, J.M., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1 (1994), 405–413.
11. [11] Linsley, P.S., Brady, W., Urnes, M., Grosmaire, L.S., Damle, N.K., Ledbetter, J.A., CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174 (1991), 561–569.
12. [12] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
13. [13] Weber, J.S., Hamid, O., Chasalow, S.D., Wu, D.Y., Parker, S.M., Galbraith, S., et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother 35 (2012), 89–97.
14. [14] Tarhini, A.A., Edington, H., Butterfield, L.H., Lin, Y., Shuai, Y., Tawbi, H., et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS ONE, 9(2), 2014, e87705.
15. [15] Hodi, F.S., Butler, M., Oble, D.A., Seiden, M.V., Haluska, F.G., Kruse, A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105 (2008), 3005–3010.
16. [16] Klein, O., Ebert, L.M., Nicholaou, T., Browning, J., Russell, S.E., Zuber, M., et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 15 (2009), 2507–2513.
17. [17] Romano, E., Kusio-Kobialka, M., Foukas, P.G., Baumgaertner, P., Meyer, C., Ballabeni, P., et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA 112:19 (2015), 6140–6145.
18. [18] Meyer, C., Cagnon, L., Costa-Nunes, C.M., Baumgaertner, P., Montandon, N., Leyvraz, L., et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 63 (2014), 247–257.
19. [19] Holmgaard, R.B., Zamarin, D., Munn, D.H., Wolchok, J.D., Allison, J.P., Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 210 (2013), 1389–1402.
20. [20] Munir, S., Larsen, S.K., Iversen, T.Z., Donia, M., Klausen, T.W., Svane, I.M., et al. Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase. PLoS ONE, 7(4), 2012, e34568.
21. [21] Sorensen, R.B., Berge-Hansen, L., Junker, N., Hansen, C.A., Hadrup, S.R., Schumacher, T.N., et al. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS ONE, 4(9), 2009, e6910.
22. [22] Melief, C.J.M., van der Burg, S.H., Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8 (2008), 351–360.
23. [23] Bjoern, J., Nitschke, N.J., Iversen, T.Z., Schmidt, H., Fode, K., Svane, I.M., Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology, 5, 2016, e1100788.
24. [24] Freeman, H.J., Colitis associated with biological agents. World J Gastroenterol 18:16 (2012), 1871–1874.
25. [25] Sørensen, R.B., Hadrup, S.R., Svane, I.M., Hjortsø, M.C., Thor Straten, P., Andersen, M.H., Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 117 (2011), 2200–2210.
26. [26] Iversen, T.Z., Engell-Noerregaard, L., Ellebaek, E., Andersen, R., Larsen, S.K., Bjoern, J., et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 20 (2014), 221–232.
27. [27] Yan, Y., Zhang, G.-X., Gran, B., Fallarino, F., Yu, S., Li, H., et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol 185:10 (2010), 5953–5961.
28. [28] Zoso, A., Mazza, E.M.C., Bicciato, S., Mandruzzato, S., Bronte, V., Serafini, P., et al. Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. Eur J Immunol 44:11 (2014), 3307–3319.
29. [29] Kleinewietfeld, M., Starke, M., Di Mitri, D., Borsellino, G., Battistini, L., Rötzschke, O., et al. CD49d provides access to “untouched” human Foxp3+ Treg free of contaminating effector cells. Blood 113 (2009), 827–836.
30. [30] Himmel, M.E., MacDonald, K.G., Garcia, R.V., Steiner, T.S., Levings, M.K., Helios+ and Helios– cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J Immunol 190 (2013), 2001–2008.
31. [31] Deaglio, S., Dwyer, K.M., Gao, W., Friedman, D., Usheva, A., Erat, A., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204 (2007), 1257–1265.
32. [32] Thornton, A.M., Korty, P.E., Tran, D.Q., Wohlfert, E.A., Murray, P.E., Belkaid, Y., et al. Expression of Helios, an Ikaros transcription factor family member, differentiatesthymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 184 (2010), 3433–3441.
33. [33] Phan, G.Q., Yang, J.C., Sherry, R.M., Hwu, P., Topalian, S.L., Schwartzentruber, D.J., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:14 (2003), 8372–8377.
34. [34] Sanderson, K., Scotland, R., Lee, P., Liu, D., Groshen, S., Snively, J., et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23 (2005), 741–750.
35. [35] Sarnaik, A.A., Yu, B., Yu, D., Morelli, D., Hall, M., Bogle, D., et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 17 (2011), 896–906.
36. [36] Yuan, J., Ginsberg, B., Page, D., Li, Y., Rasalan, T., Gallardo, H.F., et al. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 60 (2011), 1137–1146.
37. [37] Postow, M.A., Callahan, M.K., Barker, C.A., Yamada, Y., Yuan, J., Kitano, S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:10 (2012), 925–931.
38. [38] Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 (2013), 122–133.
39. [39] Chen, W., Liang, X., Peterson, A.J., Munn, D.H., Blazar, B.R., The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 181 (2008), 5396–5404.
40. [40] Mellor, A.L., Munn, D.H., IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4:10 (2004), 762–774.
41. [41] Zhao, Q., Kuang, D.-M., Wu, Y., Xiao, X., Li, X.-F., Li, T.-J., et al. Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages. J Immunol 188 (2012), 1117–1124.
42. [42] Takao, M., Okamoto, A., Nikaido, T., Urashima, M., Takakura, S., Saito, M., et al. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 17 (2007), 1333–1339.
43. [43] Muller, A.J., DuHadaway, J.B., Donover, P.S., Sutanto-Ward, E., Prendergast, G.C., Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11 (2005), 312–319.
44. [44] Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12 (2006), 1144–1151.
45. [45] Wong, R.K., Lee, J.K., Huang, J.J., Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep 6 (2012), 423–426.
46. [46] Bernardo, D., Vallejo-Díez, S., Mann, E.R., Al-Hassi, H.O., Martínez-Abad, B., Montalvillo, E., et al. IL-6 promotes immune responses in human ulcerative colitis and induces a skin-homing phenotype in the dendritic cells and Tcells they stimulate. Eur J Immunol 42 (2012), 1337–1353.
47. [47] Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52 (2003), 65–70.
48. [48] Cherayil, B.J., Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. Inflamm Bowel Dis 15 (2009), 1391–1396.
49. [49] Kim, H.-J., Cantor, H., CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res 2 (2014), 91–98.
50. [50] Klugewitz, K., Scheffold, A., Radbruch, A., Hamann, A., Transfer of IFNgamma-depleted CD4(+) T cells together with CD8(+) T cells leads to rejection of murine kidney sarcoma in mice. Int J Cancer 87 (2000), 673–679.
51. [51] Eftimie, R., Bramson, J.L., Earn, D.J.D., Modeling anti-tumor Th1 and Th2 immunity in the rejection of melanoma. J Theor Biol 265 (2010), 467–480.
52. [52] Ascierto, P.A., Napolitano, M., Celentano, E., Simeone, E., Gentilcore, G., Daponte, A., et al. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med, 8, 2010, 76.
53. [53] Zou, W., Restifo, N.P., T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10 (2010), 248–256.
54. [54] Inderberg-Suso, E.-M., Trachsel, S., Lislerud, K., Rasmussen, A.-M., Gaudernack, G., Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 1 (2012), 670–686.
55. [55] Keilholz, U., Martus, P., Scheibenbogen, C., Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 12:7 Pt 2 (2006), 2346s–2352s.
56. [56] Mougiakakos, D., Jitschin, R., von Bahr, L., Poschke, I., Gary, R., Sundberg, B., et al. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia 27 (2013), 377–388.
57. [57] Bjoern, J., Juul Nitschke, N., Zeeberg Iversen, T., Schmidt, H., Fode, K., Svane, I.M., Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology, 5(4), 2016, e1100788.
58. [58] Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:23 (2014), 2189–2199.
59. [59] Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:10 (2012), 883–892.